Koers DelMar Pharmaceuticals Inc Nasdaq
Aandelen
US2470782077
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 6,82 mln. 6,3 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -22 mln. -20,32 mln. | Nettowinst (verlies) 2023 | -14 mln. -12,93 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 11,78 mln. 10,88 mln. | Nettoliquiditeiten 2023 | 2,61 mln. 2,41 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-0,54
x | K/w-verhouding 2023 |
-0,43
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,86% |
Recentste transcriptie over DelMar Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Hoffman
CEO | Chief Executive Officer | 58 | 11-04-18 |
Greg Johnson
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Hoffman
CEO | Chief Executive Officer | 58 | 11-04-18 |
Tamara Favorito
BRD | Director/Board Member | 65 | 29-04-21 |
Laura Douglass
BRD | Director/Board Member | 59 | 26-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,63% | 114 mld. | |
+13,17% | 107 mld. | |
-12,76% | 22,22 mld. | |
-2,47% | 21,28 mld. | |
-4,97% | 18,8 mld. | |
-7,19% | 17,51 mld. | |
-39,93% | 17,17 mld. | |
+6,67% | 14,14 mld. | |
+33,90% | 12,2 mld. |